EU MDR Regulation (EU) 2017/745 transformed post-market surveillance from a passive reporting activity into an active, data-driven lifecycle obligation. Articles 83 through 86 define a mandatory system structure: a documented PMS system, a device-specific PMS plan, periodic PMS reports for Class I devices, and Periodic Safety Update Reports (PSURs) for Class IIa through III devices. The December 2025 MDCG 2025-10 guidance provides the most detailed official interpretation of these obligations to date, clarifying how to build, operate, and integrate a compliant PMS system within your QMS. This guide covers everything manufacturers need to know.

What Is Post-Market Surveillance Under EU MDR?

Post-market surveillance is the ongoing, proactive process of collecting and analyzing real-world performance data from medical devices once they are placed on the EU market. Under EU MDR (Regulation 2017/745/EU), PMS is not a reactive complaint-handling function. It is a systematic, proactive process integrated into the manufacturer's Quality Management System to continuously verify that devices remain safe, perform as intended, and meet general safety and performance requirements throughout their entire market lifetime.

Article 10(10) of the MDR mandates that every manufacturer establish, document, implement, maintain, update, and improve a PMS system appropriate to the risk class and type of device. This obligation applies regardless of device class, from Class I to Class III.

The critical shift from the predecessor Medical Device Directive (MDD) is one of intent. Under the MDD, PMS was often treated as a periodic reporting exercise. Under MDR, it is a living system that feeds back into clinical evaluation, risk management, design control, and technical documentation updates continuously.

Why EU MDR Raised the PMS Bar

The increased PMS rigor under MDR was a direct response to real-world device safety failures. The PIP breast implant scandal, metal-on-metal hip replacement complications, and surgical mesh problems all revealed a systemic failure: devices with deteriorating real-world performance stayed on the market too long because post-market data was not systematically collected, analyzed, or escalated to corrective action.

MDR's response was structural. Under the regulation:

• PMS plans are device-specific, not general system documents
• Notified Bodies have expanded oversight access to PMS reports and PSURs during surveillance audits
• PSUR update frequencies are defined by risk class with firm deadlines
• Post-Market Clinical Follow-Up (PMCF) is required for most devices unless explicitly justified otherwise
• Proactive data gathering from multiple defined sources is mandatory

Manufacturers who build rigorous PMS systems gain a measurable advantage in Notified Body interactions and demonstrate the kind of proactive safety governance that regulators now explicitly expect.

The 4 Core PMS Articles: 83 Through 86

Article 83: The PMS System

Article 83 defines the foundational requirement: every manufacturer must establish, document, implement, maintain, and continuously improve a PMS system. This system must actively gather post-market data from defined sources, analyze it for safety signals and performance trends, and feed findings back into risk management, clinical evaluation, and QMS processes.

The PMS system is not a document. It is a connected operational process that links complaint handling, vigilance reporting, PMCF, field safety corrective actions, and CAPA into a coherent feedback loop.

Article 84: The PMS Plan

Article 84 requires a documented PMS plan for each device, specifying:

• What data will be gathered and from which specific sources
• The methods and processes for data collection, storage, and analysis
• Defined threshold criteria that trigger CAPA or field safety corrective action
• Explicit reference to the clinical evaluation and risk management processes that PMS data feeds into

The PMS plan is a living document. When PMS data generates new risk insights, the plan updates accordingly. Notified Bodies review PMS plans during initial certification audits and at every surveillance audit, making plan quality a direct factor in certification outcomes.

Article 85: The PMS Report (PMSR)

Article 85 applies to Class I devices. Manufacturers must document PMS findings in a Post-Market Surveillance Report that summarizes results, analyzes conformity with general safety and performance requirements, presents a benefit-risk determination, and records any CAPA taken. The PMSR must be updated when PMS activities generate new relevant findings and must be available to competent authorities upon request.

Article 86: The Periodic Safety Update Report (PSUR)

Article 86 applies to Class IIa, IIb, and III devices and represents the most rigorous PMS reporting obligation under MDR.

PSURs must be updated at the following minimum frequencies:

• Class IIa: At least every 2 years
• Class IIb and III: At least annually

Each PSUR must include: the conclusions of the benefit-risk determination, main findings from PMCF, volume of sales and estimated population using the device, and a complete summary of PMS data analyzed with rationale for any corrective or preventive actions taken.

Class IIb and III PSURs must be submitted to the Notified Body. Class IIa PSURs must be available to the Notified Body on request. Both are reviewed during Notified Body surveillance activities.

What Data Sources Feed a PMS System?

A compliant PMS system draws from a defined, broad set of data sources. MDCG 2025-10 provides detailed guidance on the minimum expected inputs:

Reactive data sources:

• Customer complaints and device user feedback
• Vigilance reports from competent authorities
• Post-market adverse events reported by users, patients, or healthcare institutions
• Field safety corrective action (FSCA) data from similar devices on the market

Proactive data sources:

• Systematic literature searches covering the device type, equivalent devices, and relevant clinical areas
• PMCF studies, device registries, and structured patient or user surveys
• Market surveillance data from competent authorities and Notified Bodies
• Analysis of returned, repaired, or scrapped devices
• Feedback networks from distributors and healthcare providers

Every data source must be described in the PMS plan, including search methodology, frequency, responsible person, and the process by which findings are assessed against defined threshold criteria.

Post-Market Clinical Follow-Up (PMCF)

PMCF is a subset of PMS activities focused specifically on post-market clinical data collection. Under EU MDR Annex XIV Part B, PMCF is required unless the manufacturer explicitly justifies why it is not applicable to a specific device.

PMCF activities include:

• Prospective clinical investigations using the device in its intended patient population
• Clinically relevant data from literature reviews, device registries, or structured user surveys
• Structured feedback programs with healthcare institutions using the device

PMCF findings must feed directly into the clinical evaluation and Clinical Evaluation Report (CER), the technical documentation, and the risk management file. MDCG 2025-10 reinforces this closed-loop requirement: PMCF is not a standalone project but a continuous input into the full technical documentation ecosystem that sustains the device's CE marking.

Vigilance: Serious Incidents and FSCAs

Vigilance reporting under EU MDR (Articles 87-90) operates in parallel with PMS but responds to specific triggering events. Manufacturers must report to the competent authority of the relevant Member State:

• Serious incidents (events that led or could lead to patient death, serious deterioration in health, or serious public health threat): within 15 days of becoming aware
• Field Safety Corrective Actions (FSCAs): reported through a Field Safety Notice (FSN) before implementation wherever possible

An adverse event investigation that identifies a device-related root cause must trigger both a vigilance report and a CAPA. MDCG 2025-10 makes clear that the PMS system must define explicit processes for identifying potential serious incidents within complaint and feedback data streams, with documented escalation criteria and named responsible persons.

Vigilance data is also a required input into the PSUR. Unreported or delayed incidents create gaps not only in vigilance compliance but in the accuracy of the periodic safety update analysis itself.

MDCG 2025-10: What the December 2025 Guidance Adds

The Medical Device Coordination Group published MDCG 2025-10 in December 2025, providing the most comprehensive official interpretation of EU MDR PMS requirements to date. Key guidance elements that manufacturers must address:

• QMS integration: MDCG 2025-10 reinforces that PMS must be embedded within and connected to the full QMS, with defined interfaces to risk register processes, clinical evaluation, CAPA, and technical documentation. Standalone PMS binders do not meet MDR intent.
• Active, not reactive, surveillance: Guidance emphasizes that waiting for complaints to arrive does not satisfy the MDR's proactivity requirement. Manufacturers must design systems that actively seek real-world performance data.
• Quantified thresholds and triggers: MDCG 2025-10 expects manufacturers to define quantitative or qualitative threshold criteria that trigger CAPA or FSCA initiation when breached. Vague assessment language is not sufficient.
• IVD applicability: The guidance covers both MDR (2017/745) and IVDR (2017/746), applying the same PMS framework to in vitro diagnostic devices.
• Proportionality: PMS plans, reports, and PMCF scope should be proportionate to the device's risk class, intended population, and complexity of clinical use.

Manufacturers who have not yet reviewed and updated their PMS plans in light of MDCG 2025-10 face potential major findings at their next Notified Body surveillance audit.

Integrating PMS Into Your QMS

A PMS system that operates in isolation produces compliance artifacts but not compliance outcomes. True MDR conformity requires PMS to function as a connected element within the full QMS.

PMS findings must have documented pathways to:

• Risk management: New safety signals and threshold breaches update the risk file and the benefit-risk determination in the CER
• Clinical evaluation: PMCF data and real-world evidence feed into the CER on the cadence defined in the PMS plan
• CAPA: Identified trends or threshold breaches initiate formal root cause investigations and deviation CAPAs with defined timelines
• Technical documentation: Updated risk files and clinical evaluations require corresponding updates to the technical documentation supporting CE marking
• Management review: PMS trend data and PSUR conclusions should appear as standing agenda items

Managing these connections across disconnected spreadsheets, email threads, and shared drives creates version control failures, traceability gaps, and missed escalation windows. An integrated QMS platform that connects PMS data to CAPA, clinical evaluation, risk management, and document control removes these gaps structurally.

How Cloudtheapp Supports EU MDR PMS Compliance

Building a compliant EU MDR PMS system on manual tools is both time-consuming and structurally fragile. Cloudtheapp's AI-powered QMS platform provides medical device manufacturers with an integrated environment for every PMS obligation:

• Complaint and adverse event capture linked directly to PMS analysis workflows and threshold monitoring
• PMCF data collection modules connected to clinical evaluation and CER management records
• CAPA initiation triggered automatically from PMS threshold breaches with full traceability
• PSUR and PMSR report generation with audit-ready traceability back to underlying PMS data
• Risk management integration: PMS findings update risk assessments in real time
• Management review dashboards surfacing PMS trends alongside CAPA performance and audit results

Because Cloudtheapp is validated per FDA QMSR, ISO 13485:2016, and ISO 9001, every PMS record generated in the platform meets both EU MDR and global QMS standards. Manufacturers operating in EU and US markets maintain a single compliant record set rather than parallel systems.

Ready to build a PMS system that holds up under MDCG 2025-10 and Notified Body scrutiny? Request a demo to see how Cloudtheapp connects every EU MDR PMS obligation end to end.

Conclusion

EU MDR post-market surveillance is a mandatory, proactive, and deeply interconnected compliance obligation. Articles 83 through 86 define the structural requirements. MDCG 2025-10 clarifies what "good" looks like in practice. And an integrated QMS is the only architecture that sustains these requirements without creating unsustainable manual overhead.

Manufacturers who treat PMS as a living system rather than a periodic reporting task produce better safety outcomes, pass Notified Body scrutiny more consistently, and build the real-world evidence base that the next generation of clinical evaluation demands.

This post created by and appeared first on Cloudtheapp

Choosing quality management software for a regulated industry organization requires evaluating regulatory alignment, configurability, validation documentation, deployment model, and vendor expertise. The right platform reduces compliance risk, accelerates audit readiness, and scales with your organization as regulatory demands evolve.

What Is Quality Management Software?

Quality management software is a digital platform that helps organizations document, manage, and improve the processes that determine product and service quality. In regulated industries, quality management software is the operational backbone of compliance with ISO 9001, ISO 13485, FDA 21 CFR Part 820, and GMP regulations.

At its most functional level, quality management software replaces manual, paper-based processes with automated workflows, electronic approvals, traceable records, and real-time performance data. It connects quality events — deviations, CAPAs, change requests, complaints, supplier issues — into a single, coherent quality system where every record is controlled, searchable, and audit-ready.

According to Polaris Market Research, the global quality management software market was valued at $11.05 billion in 2024 and is projected to grow at 11.7% CAGR through 2034. Demand is driven by tightening regulatory requirements, digital transformation initiatives, and the proven operational ROI of modern quality platforms.

Why the Wrong QMS Can Cost You

The choice of quality management software has direct implications for regulatory standing, product quality, and operational efficiency. An inadequate system — or one not built for your industry — creates multiple risk categories:

Validation burden. Some platforms require extensive customer-side validation before regulated use. This consumes months of quality engineering time and delays your go-live significantly.

Configuration rigidity. Generic platforms designed for broad markets often cannot accommodate industry-specific workflows, regulatory forms, or data structures. Teams end up working around the system rather than with it.

Upgrade disruption. Legacy platforms with complex, infrequent upgrade cycles require internal resources to manage each release. In regulated environments, each upgrade may require re-validation, adding cost and risk.

Audit exposure. Systems that lack immutable audit trails, proper version control, or 21 CFR Part 11-compliant electronic signatures create documentation gaps that surface directly in FDA and ISO audits.

Scalability limits. Point solutions designed for one site or one quality process fail to support growth across products, sites, and geographies without significant additional investment.

7 Criteria for Choosing Quality Management Software

1. Regulatory Alignment and Pre-Validation

Your quality management software must be aligned with the specific regulations governing your industry. For medical devices: ISO 13485 and FDA 21 CFR Part 820 (QMSR). For pharmaceuticals: 21 CFR Parts 210 and 211, GMP. For food and beverage: ISO 22000/FSSC 22000.

Pre-validated platforms come with a complete Computer System Validation (CSV) package including IQ/OQ/PQ documentation, traceability matrices, and test scripts. This reduces your validation effort to execution rather than creation.

2. No-Code Configurability

Every organization has unique quality processes. Quality management software should adapt to your workflows through no-code configuration rather than forcing your processes into rigid templates.

No-code platforms let quality managers create new forms, modify approval workflows, and build applications without developer involvement. This reduces implementation timelines from months to weeks and enables continuous improvement of your quality system without IT dependency.

3. Integrated Quality Applications

A complete quality management software platform integrates all quality processes in a single environment: document control, deviation CAPA, change management, training, audits, complaints, batch records, risk management, and supplier quality management.

Siloed point solutions create traceability gaps between quality events. A CAPA opened from a deviation should link directly to the original deviation report, the root cause investigation, and the effectiveness verification record. This cross-process traceability is only possible in an integrated platform.

4. AI and Analytics Capabilities

Modern quality management software incorporates AI to identify recurring deviation patterns, surface emerging risks, and accelerate CAPA root cause investigations. Built-in analytics dashboards provide quality leadership with real-time visibility into open quality events, training compliance status, audit schedules, and system-wide trends.

Organizations that rely on manual reporting or periodic data exports miss the in-period signals that enable proactive quality management.

5. Cloud-Native Architecture

Cloud-native quality management software on established infrastructure like AWS delivers the reliability, security, and scalability that regulated industries require. Cloud platforms eliminate on-premise hardware costs, provide disaster recovery by design, and scale as your organization grows.

6. Seamless Validated Upgrades

Regulatory requirements evolve continuously. Your quality management software must keep pace without requiring your team to manage upgrade projects.

Look for vendors that push validated, automatic updates to all customers simultaneously. This ensures your system stays compliant as standards change, without the cost and disruption of manual upgrade cycles.

7. Vendor Domain Expertise and Support

In regulated industries, implementation support requires deep knowledge of GxP, FDA, and ISO expectations — not just general software knowledge. Evaluate the vendor's industry experience, implementation methodology, and ongoing support model before committing.

Unmatched customer support — from onboarding through daily operations — separates platforms that deliver long-term value from those that become frustrating IT projects.

Industry-Specific Considerations

Pharmaceutical and Biotech. Look for platforms with built-in support for batch records, annual product reviews, deviation management, and GMP-aligned document control. Data integrity compliance with 21 CFR Part 11 and EU Annex 11 is non-negotiable.

Medical Devices. Platforms must support design controls, risk management (ISO 14971), supplier quality management, and the post-market surveillance requirements introduced by EU MDR and the FDA's updated QMSR. Traceability from design through production is essential for 510(k) submission readiness.

Food and Beverage. HACCP, supplier qualification, FSSC 22000, and traceability from ingredient to finished product are the core quality requirements. Quality management software in this space must handle high-volume, batch-based production with rapid audit response capabilities.

Manufacturing. Non-conformance management, calibration and maintenance records, inspection management, and ERP integration are the primary quality software requirements for discrete and process manufacturers.

Red Flags to Avoid

Watch for these warning signs when evaluating quality management software:

• The platform requires customers to perform full IQ/OQ/PQ validation from scratch with no vendor-provided package.
• Configuration requires coding or professional services for basic workflow changes.
• Upgrade cycles are annual or biannual, with known disruption and re-validation requirements.
• The platform lacks a native, immutable audit trail and 21 CFR Part 11-compliant electronic signature capability.
• The vendor has limited regulated industry experience.
• Multi-environment configuration management (Dev, QA, Prod) is unavailable or cost-prohibitive.

Cloudtheapp: Purpose-Built Quality Management Software

Cloudtheapp checks every criterion above. It is an AI-powered, no-code, cloud-native quality management software platform purpose-built for pharmaceutical, medical device, biotech, food and beverage, and manufacturing organizations.

The platform includes 45+ pre-built applications covering every core quality process in a single FDA-validated environment on AWS. No-code designers and AI-driven configuration let quality teams build and deploy workflows in minutes without coding. Validated updates are automatic, free, and delivered to all customers simultaneously.

Cloudtheapp supports multi-environment configuration management (Dev, QA, Production) with single-click deployment in under 3 seconds. The platform is compliant with FDA 21 CFR Part 820 (QMSR), ISO 13485, ISO 9001, ISO 22001, and 21 CFR Part 11 — and a complete validation package accompanies every platform update.

Request a demo or start a 30-day free trial to see how Cloudtheapp delivers quality management software built for the demands of regulated industries.

Conclusion

Choosing quality management software is one of the most consequential technology decisions a regulated industry organization makes. The right platform accelerates compliance, reduces audit risk, and gives quality teams the tools they need to manage quality at scale.

The wrong platform means months of validation work, inflexible workflows, and systems that fall behind evolving regulatory requirements.

Use the seven criteria above to evaluate platforms objectively, and prioritize vendors with proven regulatory domain expertise, pre-validated platforms, and no-code configurability designed for the pace of modern quality management.

This post created by and appeared first on Cloudtheapp